AstraZeneca

ORZORA

NCT02476968

JCP023

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

Status:

Closed to Accrual

26459-200.png

IV

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Relapsed / Recurrent / Refractory

Disease Stage

Target.png

Biomarker(s)

BRCA1/2

Investigational

Product

Olaparib

PARP inhibitor (p.o.)

Treatment Arms

o Olaparib